Omega Diagnostics Group PLC Confirmation of Preliminary Results (1460V)
August 08 2022 - 02:00AM
UK Regulatory
TIDMODX
RNS Number : 1460V
Omega Diagnostics Group PLC
08 August 2022
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Confirmation of Preliminary Results
Investor Presentation
Omega (AIM: ODX), the specialist medical diagnostics company
focused on industry-leading Health & Nutrition products,
confirms it will issue its preliminary results for the year ended
31 March 2022 on Thursday 18 August 2022.
Investor presentation
Jag Grewal, CEO and Chris Lea, CFO will provide a live
presentation relating to the preliminary Results via the Investor
Meet Company platform on Thursday 18 August 2022 at 4:30pm BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Omega Diagnostics Group plc via:
https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor
Investors who already follow Omega Diagnostics Group plc on the
Investor Meet Company platform will automatically be invited.
Contacts:
Omega Diagnostics Group PLC www.omegadx.com
Jag Grewal, Chief Executive Officer via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley/George Dollemore
(Corporate Finance)
Alice Lane/ Harriet Ward (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro
diagnostic products for use in hospitals, clinics, laboratories and
healthcare practitioners in over 70 countries and is now focused on
the health and nutrition sector.
www.omegadx.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBSGDILXGDGDU
(END) Dow Jones Newswires
August 08, 2022 02:00 ET (06:00 GMT)
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Mar 2023 to Mar 2024